Search results for "Highlights"

Results 1 - 10 of about 387 for "Highlights".
Sort by: Relevance | Newest | Oldest

Newer oral diabetes meds could provide significant benefits in type 1 diabetes

A retrospective chart review found that glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors were associated with benefits including weight loss and reduced use of insulin in patients with type 1 diabetes.
11 Nov 2022

Annual screening for albuminuria may not be necessary in all patients with type 1 diabetes

A recent study found that personalizing the timing of testing based on patients' albumin excretion rate and HbA1c level could reduce time with undetected kidney disease as well as testing frequency.
11 Nov 2022

Diabetes and prior CVD may no longer carry equivalent cardiovascular risk

In a population-based Canadian study, the magnitude of the association between diabetes and risk of cardiovascular events decreased while that between cardiovascular disease (CVD) and such events remained stable.
11 Nov 2022

Time-restricted eating may help improve metabolic status

People who time-restricted their eating had decreased body weight and fat mass and improved lipid values but did not show improvements in waist circumference, HbA1c level, or blood pressure, a systematic review and meta-analysis found.
14 Oct 2022

Avoiding hypoglycemia most compelling reason for deintensifying diabetes meds

Researchers presented older adults with type 2 diabetes with three scenarios in which deintensification may be indicated—poor health, limited life expectancy, and high hypoglycemia risk—and found that 8%, 4%, and 75%, respectively, viewed deintensification positively.
14 Oct 2022

Gestational diabetes associated with risks later in life, but lifestyle makes a difference, studies find

A review found increased risks of cardiovascular and cerebrovascular disease in women who had gestational diabetes, while another study showed that five markers of a healthy lifestyle were associated with a significant reduction in risk of developing type 2 diabetes after gestational diabetes.
14 Oct 2022

Spotlight on diabetes drug class comparisons

A large trial compared insulin, a sulfonylurea, a glucagon-like peptide-1 (GLP-1) receptor agonist, and a dipeptidyl peptidase-4 inhibitor as second-line therapy, while a modeling study considered GLP-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors as first-line agents.
14 Oct 2022

ADA, KDIGO offer consensus statements on managing diabetes and chronic kidney disease

The American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) provided specific advice on use of metformin, sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and nonsteroidal mineralocorticoid receptor antagonists in patients with diabetes and chronic kidney disease.
14 Oct 2022

Patients diagnosed by OGTT without elevated HbA1c had similar CV, renal disease risks as those without diabetes

A prospective U.K. study found that patients with diabetes based on an oral glucose tolerance test (OGTT) often did not have a diabetic HbA1c level, and risks of cardiovascular (CV) and kidney disease in these patients were similar to those in the nondiabetic general population.
16 Sep 2022

Program directs stable diabetes patients from endocrinology back to primary care

One academic health system developed a program to “graduate” patients out of endocrinology visits for their diabetes. Criteria included HbA1c level less than 8.0%, blood pressure less than 140/90 mm Hg, no tobacco use, and use of statins and aspirin if needed.
16 Sep 2022

Result Page: Prev   1   2   3   4   5   6   7   8   9   10   Next